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ABSTRACT 
Hepatocellular carcinoma or Liver cancer (LC) is the sixth most common cancer and the fourth cause of death 
worldwide in 2018. There has not been a comprehensive study on the survival rate of patients with LC in Asia yet. 
Therefore, the present study was conducted to evaluate the survival rate of patients with LC in Asian countries. 
The methodology of the present study is based on the PRISMA (Preferred Reporting Items for Systematic Reviews 
and Meta-Analysis) statement. The researchers searched five international databases including Medline/PubMed, 
Scopus, Embase, Web of Knowledge and ProQuest until July 1, 2018. We also searched Google Scholar for de-
tecting grey literature. The Newcastle-Ottawa Quality Assessment Form was used to evaluate the quality of se-
lected papers. A total of 1425 titles were retrieved. 63 studies met the inclusion criteria. Based on the random-
effect model one-year, three-year and five-year survival rate of LC were 34.8 % (95 % CI; 30.3-39.3), 19 % (95 % 
CI ; 18.2-21.8) and 18.1 % (95 % CI ;16.1-20.1) respectively. According to the results of our study, the LC survival 
rate in Asian countries is relatively lower than in Europe and North America. 
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INTRODUCTION 
Cancer is one of the major health prob-
lems today and is currently one of the leading 
causes of death in many countries (Bray et al., 
2018). Among malignancies, liver cancer 
(LC) is one of the most common one, of 
which more than 85 % of cases of LC has 
been observed in developing countries 
(Global Burden of Disease Cancer 
Collaboration et al., 2017). The highest inci-
dence of this cancer is in Asian and sub-Sa-
haran Africa (Ladep et al., 2014). Evidence 
suggests that the incidence of this cancer is 
soaring (McGlynn et al., 2015), which has 
been observed in Europe, the Pacific, as well 
as Asian countries (La Vecchia et al., 2000; 
Mirzaei et al., 2016; Mohammadian et al., 
2016; Hassanipour et al., 2019). In terms of 
mortality, the standardized mortality rate of 
LC is 5.9 per 100,000. Due to the very poor 
prognosis of LC, the mortality rate is 95 % 
(Torre et al., 2016; Nikbakht et al., 2019). 
Global variation in LC rates can be explained 
by the distribution of viral hepatitis B and C 
infection, that should be mentioned here, the 
two viruses alone account for 78 % of the total 
mortality rate of LC in the world (Zamor et 
al., 2017; Jakupi et al., 2018). There is also 
evidence that the incidence of LC in Asia is 
declining in many Asian countries as a result 
of hepatitis B vaccination (Mansour-Ghanaei 
et al., 2007; Yeo et al., 2013; Joukar et al., 
2018; Aniaku et al., 2019). Liver cirrhosis is 
another major risk factor, of which 80-90 % 
of these patients have hepatocellular carci-
noma (Gao et al., 2012). LC is one of the ma-
lignancies that have been studied by genetics, 
and in this case the relative risk for a person 
with family history is 6.2 (Fernandez et al., 
1994; Turati et al., 2012) and also it is signif-
icantly higher in males than in women 
(Naugler et al., 2007). 
 The main affecting factors for long-term sur-
vival in these patients are, early diagnosis of 
tumors, and treatment of patients with effec-
tive therapies (Wang et al., 2008). Patients di-
agnosed at an early stage will be more likely 
to respond to treatment and have long-term 
survival (Yuen et al., 2000) Also, in order to 
diagnose these patients at an early-stage, 
monitoring high risk people is a key and im-
portant factor (Zhang et al., 2004).  
Survival rate is one of the most important 
health indicators that is essential in evaluating 
diagnostic and therapeutic programs. The first 
step to control the burden of disease related to 
cancers in any population, is to understand its 
status in the population, as well as to collect 
information about the incidence, survival, 
type and location of cancers. It is necessary to 
record effective indicators on the process and 
survival of cancers in a monitoring area and 
patients' information in order to perform the 
correct and appropriate treatment and to apply 
effective therapeutic methods and prevention 
strategies. In spite of increasing cancer treat-
ment costs in developing countries, a few re-
searches that were hospital-centered and pop-
ulation-based information have been con-
ducted. Studies on the survival of LC in Asian 
countries have achieved various results, and 
the studied population in these surveys has 
also been different. Familiarity with the vari-
ous years of survival rate of this cancer in dif-
ferent countries as well as different popula-
tion groups can provide valuable information 
on the control, prevention, and treatment out-
comes of patients with LC. There has not been 
a comprehensive study on the survival rate of 
patients with LC in Asia yet. Therefore, ac-
cording to the mentioned points, the present 
study was conducted to evaluate the survival 
rate of patients with LC in Asian countries. 
 
METHODS 
The present study is a systematic review 
and meta-analysis study of LC survival rate in 
Asian countries. This study was designed and 
conducted in 2018. The methodology of the 
present study is based on the PRISMA (Pre-
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ferred Reporting Items for Systematic Re-
views and Meta-Analysis) statement (Moher 
et al., 2015). 
 
Search strategy 
The researchers searched five interna-
tional databases including Medline/PubMed, 
Scopus, Embase, web of knowledge and 
ProQuest until July 1, 2018. We also searched 
the Google Scholar for detecting grey litera-
ture. Selected keywords for international da-
tabases included: (“neoplasm”, “cancer”, 
“carcinoma”, “malignancy”, “liver cancer”, 
“hepatocellular neoplasms”, “hepatocellular 
carcinoma”, “liver tumor”, “cancer of liver”, 
“neoplasms of liver”, “survival, “survival 
analysis”, “survival rate”, “Afghanistan”, 
“Armenia” ,“Azerbaijan”, “Bahrain” “Bang-
ladesh”, “Bhutan”, “Brunei”, “Myanmar”, 
“Cambodia”, “China” “Georgia”, “Hong 
Kong”, “India”, “Indonesia”, “Iran”, “Iraq”, 
“Israel”, “Japan”, “Jordan”, “Kazakhstan” 
“North Korea”, “South Korea”, “Kuwait”, 
“Kyrgyzstan”, “Laos”, “Lebanon”, “Macau”, 
“Malaysia” “Maldives”, “Mongolia”, “Ne-
pal”, “Oman”, “Pakistan”, ”Philippines”, 
“Qatar”, “Saudi Arabia”, “Singapore”, “Sri 
Lanka”, “Syria”, “Taiwan”, “Tajikistan”, 
“Thailand”, “Timor-Leste”, “Turkmenistan”, 
“United Arab Emirates”, “Uzbekistan” , ”Vi-
etnam”, and “Yemen”).  
The initial search was conducted by two 
researchers (S.H and M.V). The searched rec-
ord entered the EndNote X7 software, and du-
plicate articles were deleted. The search strat-
egy of this study is presented in Supplemen-
tary Appendix 1. 
 
Inclusion and exclusion criteria 
All observational studies (cross-sectional, 
case-control, and cohort) stated the survival 
rate of Localize LC in Asian countries were 
included in the study. Articles of other can-
cers reported survival in people who reported 
regional, metastatic, as well as review and 
meta-analysis studies were excluded. It 
should be noted that studies that did not report 
the sample size or confidence interval of sur-
vival rate were not included into the meta-
analysis. 
 
Quality assessment 
The Newcastle-Ottawa Quality Assess-
ment Form was used to evaluate the quality of 
selected papers. This tool has 3 different parts 
including Selection (4 questions), Compara-
bility (1 question) and Outcome (3 questions) 
and is based on the final scores divided into 3 
categories Good (3 or 4 stars in selection do-
main and 1 or 2 stars in comparability domain 
and 2 or 3 stars in outcome/exposure domain), 
Fair (2 stars in selection domain and 1 or 2 
stars in comparability domain and 2 or 3 stars 
in outcome/exposure domain) and Poor (0 or 
1 star in selection domain or 0 stars in compa-
rability domain or 0 or 1 stars in outcome/ex-
posure domain) (Penson et al., 2012). Result 
of quality assessment is presented in Suppple-
mentary Appendix 2. 
 
Screening of studies 
Screening of studies, extraction of results, 
and evaluation of quality control of articles 
were performed separately undependably by 
two authors (M.V and E.A). If there was no 
agreement between the two, the supervisor 
(F.M) would announce the final comment on 
that article. 
 
Data extraction form 
All final articles entered into the study 
process were provided by a checklist that was 
previously prepared, and were arranged to ex-
tract the data. This checklist includes the 
name of the author, the year of publication, 
the period of the study, the country of origin, 
the survival rate by year for each survival pe-
riod. 
 
Statistical analysis 
The heterogeneity of the studies was as-
sessed by Cochran test (with significance less 
than 0.1) and its composition using I2 statis-
tics. In the case of heterogeneity, the random 
effects model was utilized with the inverse-
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variance method, and in the absence of heter-
ogeneity, the fixed effects model was applied. 
In the case of a heterogeneity in the studies, 
methods such as subgroup analysis were used 
and factors like the geographical area and the 
HDI considered in the analysis of subgroups. 
All analyzes were performed by the STATA 
(version 13) software.  
 
Additional analysis  
Due to the heterogeneity of the studies, 
the subgroups analysis was used. The indica-
tor applied for this purpose is Human Devel-
opment Indices and Indicators (HDI). The 
HDI is a relative measure of life expectancy, 
education, quality and education level, and in 
general, it is the living standards in human so-
cieties. This Index is estimated using the 
measure of welfare, especially among chil-
dren and people of low age. These statistics 
can be used to measure the development of 
countries, the impact of economic policies on 
living standards, and the survival of LC in 
each of the countries was reported to provide 
a clear indication of the LC survival status in 
each country (Human Development Indices 
and Indicators, 2018). 
 
RESULTS 
Study selection 
After searching the named international 
databases 1425 articles were selected and af-
ter removing duplicate articles 1132 re-
mained. After reviewing the titles and abstract 
articles, the number of 178 articles entered the 
next stage, at which point the full text was ex-
amined and the 63 articles entered the final 
analysis. It should be noted that the referenced 
articles were also reviewed to add related 
studies. In the screening stages of studies, 
some articles were excluded for a variety of 
reasons, which included the unrelated topic 
(N=921), the unrelated population (N=133), 
inadequate information such as sample size, 
confidence interval and not reported overall 
survival in both sexes (N=12) and the re-
peated results (N=3). The study selection pro-
cess is outlined in Figure 1. 
 
Figure 1: Flowchart of the included studies in sys-
tematic review 
 
 
Results of quality assessment 
Based on our result, 30 studies had good 
quality and 33 studies had fair quality. The re-
sult of Quality Assessment is presented in 
Supplementary Appendix 1. 
 
Description of studies  
Based on the geographical location of 63 
included studies (Sriamporn et al., 1995; 
Chen et al., 1998; Esteban et al., 1998; Jin et 
al., 1998; Martin et al., 1998; Lee et al., 2000; 
Chia et al., 2001; Sato et al., 2002; Toyoda et 
al., 2004; Chen et al., 2006; Tsukuma et al., 
2006; Yaghi et al., 2006; Chen et al., 2007; 
Jung et al., 2007; Changchien et al., 2008; 
Lim et al., 2009; Redaniel et al., 2009; Tanaka 
et al., 2009; Laudico et al., 2010; Chen et al., 
2011; Chia, 2011; Jayalekshmi et al., 2011; 
Jayant et al., 2011; Jung et al., 2011; Kudo et 
al., 2011; Law and Mang, 2011; Martin et al., 
2011; Matsuda et al., 2011; Redaniel et al., 
2011; Sankaranarayanan, 2011; Sriplung and 
Prechavittayakul, 2011; Sumitsawan et al., 
2011; Xiang et al., 2011; Xishan et al., 2011; 
Azmawati and Krisnan, 2012; Jung et al., 
2012; Chen et al., 2013; Ito et al., 2013; Jung 
et al., 2013; Norsa'adah and Nurhazalini-
Zayani, 2013; Fan et al., 2014; Ito et al., 2014; 
Jung et al., 2014; Pinheiro et al., 2014; 
Somboon et al., 2014; Jung et al., 2015; Liu et 
EXCLI Journal 2020;19:108-130 – ISSN 1611-2156 
Received: September 23, 2019, accepted: November 19, 2019, published: January 13, 2020 
 
 
112 
al., 2015; Maringe et al., 2015; Xiao et al., 
2015; Zeng et al., 2015; Zhang et al., 2015; 
Zheng et al., 2015; Zhu et al., 2015; Chiang et 
al., 2016; Kudo et al., 2016; Oh et al., 2016; 
Jung et al., 2017; Li et al., 2017; Nakagawa-
Senda et al., 2017; Chen et al., 2018; Chien et 
al., 2018; Jung et al., 2018; Li-Hsin et al., 
2018), twenty-one studies were conducted in 
China, fourteen in Korea, nine in Japan, nine 
in Thailand, nine in Taiwan, four in Philip-
pines, four in Singapore, four in India, two in 
Malaysia, one in Hong-Kong and one study in 
south Asian countries. The summary charac-
teristics of the included studies were shown in 
Table 1. 
 
Heterogeneity  
The result of chi-squared test and the I2 in-
dex indicated that there was a considerable 
between-study heterogeneity. For one (I2= 
99.8 %, P<0.001), three (I2= 99.8 %, 
P<0.001), five (I2= 99.9 %, P<0.001) and ten- 
year survival rate (I2= 99.6 %, P<0.001). 
 
Synthesis of results 
The articles were sorted according to the 
year of publication, and then analyzed by sur-
vival analysis of 1, 3, 5 and 10 years survival 
rate based on random effect model. 
 
One-year survival rate 
Of the most recent papers, 27 studies re-
ported a one-year survival rate. The results of 
the study showed that one-year survival rate 
in Asian countries was 34.8 % (95 % CI; 30.3- 
39.3). One-year survival rate of LC based on 
HDI has been shown in Figure 2. Regarding 
the results, the highest one-year survival rate 
in countries with a very high HDI level (46 %, 
95 % CI; 38-54) and the lowest was observed 
among countries with medium HDI level 
(25.6 %, 95 % CI; 8.2-43.6).  
 
Figure 2: Forest plot of one-year survival rate of liver cancer in Asian countries
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Table 1: Basic information of included studies 
Order Author (year) Location Time period Sample size 
Survival Rate 
1 3 5 10 
male female male female male fe-male 
1 Sriamporn (1995) Thailand 1985-1992 10333 27.80 12.00 8.00  
2 Chen (1998) China 1982-1991 17331 10.70 3.10 2.00  
3 Esteban (1998) Philippines 1983-1987 1087 19.90 14.10 12.50  
4 Jin (1998) China 1988-1992 6857 14.20 5.20 3.90  
5 Martin (1998) Thailand 1988-1992 1449 6.80 1.50 .40  
6 Lee (2000) Taiwan 1987-1992 2002   15.00  
7 Chia (2001) Singapore 1983-1987 2282125   3.00  
8 Chia (2001) Singapore 1988-1992 2705115   3.00  
 
 
9 
 
 
 
Sato (2002) 
 
 
 
Japan 
 
 
1962-1966  
 
48745 
 
 
 
 
 
 
5.20 12.90  
 1967-1971 5.30 9.20 
1972-1976 7.40 22.70 
1977-1981 9.30 16.90 
1982-1986 21.50 22.60 
1987-1991 36.30 32.40 
1992-1994 42.70 40.90 
10 Toyoda (2004) Japan 1976-2000 1365   37.30  
 Tsukuma (2006) Japan 1993-1996 279000   12.30  
11 Chen (2006) Taiwan 1986-1989 479 38.60 17.30 11.10  
1990-1993 638 45.50 27.70 18.70  
1994-1997 1044 49.20 29.10 21.00  
1998-2001 975 62.40 42.90   
12 Yaghi (2006) Lebanon 1998-2003 92 44.80 17.60   
13 Chen (2007) Taiwan 1985-1994 28939   13.70 17.20  
14 Jung (2007) Korea 1993-1997 126833   10.40 13.10  
1998-2002   14.50 15.30  
15 Changchien (2008) Taiwan 1986-2002 6381 44.30 24.90 17.10  
16 Lim (2009) Singapore 1978-1982 142252    .30 .60 
1983-1987 .40 .40 
1988-1992 .80 2.20 
1993-1997 1.80 1.30 
1998-2002 6.30 1.80 
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Order Author (year) Location Time period Sample size 
Survival Rate 
1 3 5 10 
male female male female male fe-male 
17 Redaniel (2009) Philippines 1998-2002 772   8.50  
18 Tanaka (2009) Korea 1997-1999 45205   13.00  
Miyagi 24.00 
Yamagata 22.30 
Niigata 22.70 
Fukui 32.50 
Osaka 23.40 
Nagasaki 22.10 
Taiwan 17.60 
Korea 14.70 
Miyagi 22.80 
Yamagata 19.50 
Niigata 21.70 
Fukui 20.40 
Osaka 21.30 
Nagasaki 25.80 
Taiwan 20.30 
19 Laudico (2010) Philippines 1993-2002    8.50  
20 Law (2011) China 1996-2001 9256 36.90 23.00 18.90  
21 Kudo (2011) Japan 1978-1980 148161   5.10  
1981-1985 13.90 
1986-1990 24.90 
1991-1995 32.00 
1996-2000 38.80 
2001-2005 42.70 
22 Sumitsawan (2011) Thailand 1993-1997 705 17.00 4.50 3.00  
23 Matsuda (2011) Japan 1993-1999 491772   21.20  
24 Redaniel (2011) Philippines 1995-1999    5.30  
25 Chen (2011) China 1992-2000  13.50 6.80 5.60  
26 Chia (2011) Singapore 1968-1997  19.00 7.50 5.10  
27 Jayalekshmi (2011) India 1991-1997 54 34.60 9.20 2.30  
28 Jayant (2011) India 1993-2000 47 2.10 .0 .0  
29 Martin (2011) Thailand 1990-2000 1455 19.40 13.20 12.20  
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Order Author (year) Location Time period Sample size 
Survival Rate 
1 3 5 10 
male female male female male fe-male 
30 Sankaranarayanan 
(2011) 
Hong Kong SAR 
(China) 
1991-2000    24.60  
Qidong (China) 5.40 
Shanghai 
(China) 
9.80 
Tianjin (China) 25.80 
India 4.50 
Singapore 6.50 
Busan (Republic 
of Korea) 
10.00 
Incheon (Re-
public of Korea) 
16.80 
Seoul (Republic 
of Korea) 
20.30 
Chiang mai 
(Thailand) 
3.30 
Lampang  
(Thailand) 
11.90 
Songkhla  
(Thailand) 
2.50 
31 Jung (2011) Korea 1993-1995 178816   10.70  
1996-2000 13.20 
2001-2005 19.70 
2004-2008 23.30 
32 Sriplung (2011) Thailand 1990-1999 271 29.20 8.10 2.20  
33 Xiang (2011) China 1992-1995 6954 18.40 8.90 7.50  
34 Xishan (2011) China 1991-1999 6525 32.50 22.60 21.30  
35 Jung (2012) Korea 1993-1995 192561   10.70  
1996-2000   13.20  
2001-2005   20.10  
2005-2009   25.10  
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Order Author (year) Location Time period Sample size 
Survival Rate 
1 3 5 10 
male female male female male fe-male 
36 Azmawati (2012) China 2003-2006 299 60.00 39.00 21.00  
Malaysia 47.00 13.00   
India 47.00 15.00   
37 Chen (2013) China 2004-2005 633802   4.00  
38 Jung (2013) Korea 1993-1995 202053   10.70  
1996-2000 13.20 
2001-2005 20.10 
2006-2010 26.70 
39 Ito (2013) Japan 1990-2004 4800 31.00 33.00 37.00  
40 Norsa'adah (2013) Malaysia 1987-2008 259 13.00    
41 Pinheiro (2014) Hispanics and 
Asians 
2000-2008 1471789   7.10  
42 Ito (2014) Japan 1993-2009 21175   38.00 38.40 9.60 9.10 
1993-2004 30932 62.20 60.10  22.80 21.10  
43 Jung (2014) Korea 1993-1995 218017   10.70  
1996-2000 13.20 
2001-2005 20.20 
2007-2011 28.60 
44 Fan (2014) China 2004-2012 164   26.20  
531 28.30 
45 Somboon (2014) Thailand 2007-2012 308   5.00  
46 Jung (2015) Korea 1993-1995 224177   10.70  
1996-2000 13.20 
2001-2005 20.20 
2008-2012 30.10 
47 Maringe (2015) South Asians 1986-1995 8141 23.30  15.00  
1996-2004 27.30 15.00 
48 Zeng (2015) China 2003-2005 16816   10.10  
49 Liu (2015) China 1990-2009 35   14.30  
50 Xiao (2015) China 2000-2012 319 20.30 12.60 4.50  
51 Zhang (2015) China 2002-2013 365 92.30 65.30 44.70  
52 Zheng (2015) China 2000-2011 322000 27.20 12.70 8.90  
53 Zhu (2015) China 2002-2011 2045 44.00 25.00 22.00  
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Order Author (year) Location Time period Sample size 
Survival Rate 
1 3 5 10 
male female male female male fe-male 
54 Chiang (2016) Taiwan 2002-2012    28.90  
55 Kudo (2016) Japan 1967-1978 173378   37.90 16.50 
56 Oh (2016) Korea 1993-1995 225343   10.70  
1996-2000 13.20 
2001-2005 20.20 
2008-2013 31.40 
57 Nakagawa-Senda 
(2017) 
Japan 2006-2008 120503   19.30  
58 Jung (2017) Korea 1993-1995    10.70  
1996-2000 13.20 
2001-2005 20.20 
2010-2014 32.80 
59 Li (2017) Northeast China 2000-2007    10.70  
60 Chen (2018) China 2002-2014 5244 35.16 17.52 11.69 6.34 
61 Chien (2018) Taiwan 2000-2010    4.22  
62 Jung (2018) Korea 1993-1995    10.70  
1996-2000 13.20 
2001-2005 20.40 
2006-2010 28.10 
2011-2015 33.60 
63 Li-Hsin (2018) Taiwan 2000-2010 724992   4.22  
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Three-year survival rate 
There were 22 studies that reported 3-year 
survival rate. Based on the results of our 
study, the 3-year survival rate in Asian coun-
tries was 19 %, (95 % CI; 16.2-21.8). The 
three-year survival rate of LC based on HDI 
is presented in Figure 3. According to the re-
sults, the highest three-year survival rate for 
countries with a high HDI level (26.9 %, 95 
% CI; 32.3-21.5) and the lowest for countries 
with the medium HDI levels was 14 % (95 % 
CI; 18.2-12.29).  
 
Five-year survival rate 
A total of 56 studies reported this survival 
rate. The 5 years rate of LC was 18.1 % (95 % 
CI, 16.2-20.1). The results of the 5-year sur-
vival by the HDI is depicted in Figure 4. 
Based on the findings of our study, the highest 
five-year survival rate for countries with very 
high HDI levels (20.7 %, 95 % CI; 18.2-23.2) 
and the lowest was for the countries with the 
medium HDI level 8 %, 95 % CI; 5.3-10.7).  
 
Ten-year survival rate 
Four studies reported this survival rate 
and based on the results, the ten-year survival 
rate was 4.1 % (95 % CI; 1.5-6.7). Ten-year 
survival of LC by HDI has been shown in Fig-
ure 5. Given the limited number of studies 
conducted for 10-year survival rate, data on 
countries with medium HDI levels was not 
available.  
 
 
Figure 3: Forest plot of three-year survival rate of liver cancer in Asian countries
EXCLI Journal 2020;19:108-130 – ISSN 1611-2156 
Received: September 23, 2019, accepted: November 19, 2019, published: January 13, 2020 
 
 
119 
 
EXCLI Journal 2020;19:108-130 – ISSN 1611-2156 
Received: September 23, 2019, accepted: November 19, 2019, published: January 13, 2020 
 
 
120 
 
 
 
 
Figure 4: Forest plot of five-year survival rate of liver cancer in Asian countries 
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Figure 5: Forest plot of ten-year survival rate of liver cancer in Asian countries 
 
ANALYSIS OF SUBGROUPS 
Survival rate of liver cancer in each  
country 
Overall, the results of the survival of the 
LC in ten countries and another region has 
been reported in Table 2. The highest survival 
rates of one, three, five, and ten years were re-
ported in Japan and the lowest survival rates 
for these years were observed in countries 
such as the Philippines, Thailand, India and 
Singapore. 
 
Meta-regression 
Results of meta-regression showed a sig-
nificant association between publication year 
and survival rate. Thus, year of study is a 
cause of variability in results of one (Reg 
Coef= 0.041, p=0.002), three (Reg Coef= 
0.049, p=0.017) and five year survival rate 
(Reg Coef= 0.036, p<0.001). According to re-
sults, an increasing survival rate across the 
study period was observed. Results of meta-
regression has been shown in Supplementary 
Appendix 3. 
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Table 2: Result of meta-analysis of survival rate of liver cancer in Asia based on each country and year 
of survival 
Country 
Year of Survival 
# of 
study  1 
# of 
study 3 
# of 
study  5 
# of 
study  10 
China 11 35.4 (28.6-42.1) 11 20.6 (16.5-24.7) 18 14.8 (12.4-17.3) 1 6.3 (4.4-8.2) 
India 3 27.8 (4.43-60) 2 13.4 (8.3-18.4) 1 2.3 (0.6-12.8) - NR 
Japan 3 53 (36.6-69.5) 1 33 (31.6-34.3) 44 23.9 (20.1-27.7) 3 11.7 (6.7-16.7) 
Korea - NR - NR 18 18.4 (16-20.7) - NR 
Lebanon 1 44.8 (34.3-52.2) - NR - NR - NR 
Malaysia 2 29.9 (3.3-63.2) 1 13 (9-17) - NR - NR 
Philip-
pines 1 19.9 (17.4-22.3) 1 14.1 (12.1-16.3) 4 8.7 (6-11.4) - NR 
Singa-
pore - NR - NR 2 3(2.9-3.1) 10 1.3 (0.7-1.9) 
South 
Asian 2 25.9 (22-29.8) - NR 2 15 (11.6-18.3) - NR 
Taiwan 5 48 (40.9-55.2) 5 28.3 (21.6-35.1) 12 15.9 (12.9-19) - NR 
Thailand 5 20 (9.7-30.1) 5 7.8 (2.1-13.5) 6 5.1 (1-9.2) - NR 
Overall 33 34.8 (30.3-39.3) 25 19 (16.2-21.8) 107 18.1 (16.2-20.1) 14 4.1 (1.5-6.7) 
NR: not reported 
 
 
DISCUSSION 
LC is the sixth most common cancer and 
the fourth cause of death worldwide in 2018, 
with 841,000 new cases and 782,000 deaths 
annually (Bray et al., 2018). The incidence 
and mortality of men are two to three times 
higher than women in most parts of the world 
(Altekruse et al., 2014).  
The results of our study showed that one, 
three, five and ten-year survival rate of LC in 
Asian countries was 34.8 %, 19 %, 18.1 %, 
and 4.1 % respectively. Significant heteroge-
neity was seen in the between studies. The 
present study was conducted in identifying 
high-risk individuals, diagnosis and early 
treatment of LC. The most important treat-
ment for hepatocellular carcinoma is hepatic 
resection, trans-arterial embolization, percu-
taneous ethanol injection therapy, regional 
chemotherapy, and liver transplantation 
(Takano et al., 2000; Fakhar et al., 2016; Zhao 
et al., 2019). For instance, 84.5 % of patients 
in Pakistan (Yusuf et al., 2007) did not receive 
any treatment interventions, which was 
30.5 % in China (Zhou et al., 2000). Mortality 
rate for all cancers are 50 % more common in 
men than in women. Mortality rate in men 
were 171 per 100,000 in East Africa to 67.4 
in Central America, ranging from 7.1 in Mel-
anesia to 2.6 in Central and East Asia (except 
China) (Ghoncheh and Salehiniya, 2016). The 
cumulative mortality risk from cancer among 
women in East Africa (11.4 %) in 2018 was 
higher than the estimated risk in North Africa 
(8.6 %), Northern Europe (9.1 %), and Aus-
tralia / New Zealand (1.8 %) (Allemani et al., 
2018; Bray et al., 2018). In one study which 
is conducted on localized staged patients 
treated with invasive methods, blacks have a 
12 percent higher mortality rate, while Asian 
or Pacific islanders have a 16 percent lower 
mortality rate compared to whites (Wong and 
Corley, 2009). 
The statistics show that about half of the 
cases of death from primary LC occurred in 
China (Zheng et al., 2018). The variety of sur-
vival rates in Asian countries includes the 
range of medical and pharmaceutical care and 
coverage of insurance services, socioeco-
nomic status, ethnicity and lifestyle (Williams 
et al., 2010). Medical advances have been 
made in detecting small tumors with a variety 
of scanning techniques (Takayasu et al., 
1995).  
In our analysis, the one-year survival rate 
in Asian countries was 34.8 %. The one-year 
survival rate is related to factors such as age 
older than 50 years, CLIP score <3, ALP <120 
U/l, LDH <450 IU/l, CRP <0.8 mg/dl, tumor 
size less than 6 cm, disease stage, and Child-
Pugh less than 7 that is associated with in-
creased mortality (Toyoda et al., 2004; 
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Georgiades et al., 2006; Jun et al., 2013; 
Agarwal et al., 2015). A meta-analysis study 
concluded that Transarterial chemoemboliza-
tion (TACE) in patients with portal vein 
thrombosis significantly increased the 6 
months survival rate (Xue et al., 2013). How-
ever, haptoglobin (Hp) serum could be a po-
tential and alternative contributor to alpha-fe-
toprotein. Contradiction in predicting one 
year rate in various geographic regions can be 
due to the selecting patients with demo-
graphic and clinical characteristics, diagnos-
tic criteria, severity of the cirrhosis, number 
and size of the tumor (Shu et al., 2010; 
Moayedi et al., 2019). Despite the limited 
number of HCTs available for HCC, one-year 
survival rates for HCC have almost doubled 
over the period of 1992-1993 to 2003-2004 in 
the United States (Altekruse et al., 2009). Of 
course, this increase in survival is limited to 
short-term follow-up. In addition, with ag-
gressive treatments including liver transplan-
tation and resection for localized-stage tu-
mors, they are effective in boosting survival 
rates (Schwarz and Smith, 2008). It is also as-
sociated with the expansion of public health 
and oncology care (Bai et al., 2018). 
Based on the results, the five-year sur-
vival rate was 18.1 %. The 5-year survival 
rate of all cancers in Korea in each sex, 
reached to 7.70 % (2011-2015) from 2.41 % 
(1995-1993) (Jung et al., 2018). Besides, the 
five-year survival rate of LC in Shanghai in 
1990 was 0.9 percent, reaching 0.1 percent in 
the last decade (Xiang et al., 2011; Han et al., 
2012). Uninodular tumors and non-vascular 
invasion were associated with a 5-year sur-
vival (Jeong et al., 2017). Liver transplant in-
creases 5-year survival to 75 %, which is the 
best treatment option (Zamora-Valdes et al., 
2017). A meta-analysis study of 19 researches 
illustrated that the median survival rate for 
436 patients with liver resection for hepato-
cyte metastasis to gastric was 17 months and 
a 5-year survival of 26.5 % (Kerkar et al., 
2010). An overall improvement in commu-
nity health and the use of anti-viral therapies 
is effective in extending patient survival. 
Liver transplantation is an appropriate option 
(Omata et al., 2010; Zhu et al., 2015). How-
ever, the high cost of transplantation and the 
low number of donors of liver transplantation 
in most cases make it impractical (Llovet et 
al., 2005). Resection surgery is recommended 
as a treatment for BCLC (Barcelona Clinic 
Liver Cancer) in very early and primary 
phases without portal hypertension and ab-
normal bilirubin. However, resection surgery 
is now the first line of therapy and leads to 
better patient survival (Dimitroulis et al., 
2017).  
The gender variable is an independent 
predictor in the prognostic primary liver can-
cer (PLC), regardless of the death of the PLC 
and all causes of death (Chen et al., 2007). 
However, in other studies, the gender variable 
was not a predictor of survival due to PLC 
(Tangkijvanich et al., 2004; Jarnagin et al., 
2009). Previous studies have shown that 
women have a higher rate of survival after 
surgery. Differences in aspects of medical in-
terventions are attributed to gender disparity 
in survival rates (Wu et al., 2018). The high 
alcohol intake in men increases cirrhosis of 
the liver towards the PLC (Nordenstedt et al., 
2010; Kröner et al., 2015).  
Analysis of subgroups based on the geo-
graphic region show that, the highest survival 
rates of one, three, five, and ten years are re-
ported in Japan and the lowest survival rates 
for these years were observed in the Philip-
pines, Thailand, India and Singapore, respec-
tively. The only areas with a high prevalence 
rate in the past include Japan, Korea and 
China, which have witnessed a sharp decline 
in outbreaks in recent years (Bertuccio et al., 
2017). 
According to the latest global release, the 
highest incidence has taken place in lower 
HDI settings, and LC in 13 countries was one 
of the most common malignancies, including 
several countries in North and West Africa 
(Egypt, Gambia, Guinea) and the East and 
South East Asia (Mongolia, Cambodia and 
Vietnam) (Hashim et al., 2016). Also, over 
the most recent years, the mortality rate of 
HCC is 2 to 5 times higher in Japan, Hong 
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Kong and Korea than in European and Amer-
ican countries (McGlynn and London, 2011; 
Zhu et al., 2016). In the case of China, the pro-
portion of Child A was less prevalent, while 
this proportion was more prevalent in the case 
of the Italian Child B type (Pons et al., 2005; 
Azmawati and Krisnan, 2012; Kew, 2014). In 
addition, Asians have lower survival rates 
than non-Asians (Chang et al., 2007). Ad-
vances have been made in HCC management 
and treatment, through local ablation, hepatic 
resection and liver transplantation. The im-
pact of such improvements on HCC mortality 
was limited, as its 5-year survival rate was 
about 10 % (Lepage et al., 2015). The five-
year survival rate of the cancer in the US rose 
from 3 % over the 1975-1977 period to 11 % 
in the period of 2001-2007. While this sur-
vival rate ranged from 10.7 % in 1975-1977 
to 18.9 % in the period 2001-2005. Approxi-
mately 62 % of HCC patients in Japan have 
undergone resection or ablation as primary 
care (Korean Liver Cancer Study Group and 
National Cancer Center Korea, 2015). By 
comparing these proportions, only 30 % of 
these patients in the Western countries by the 
initial diagnosis were under these treatment 
interventions. Perhaps the care of high-risk 
patients will cause early detection and early 
diagnosis in countries such as Japan and Ko-
rea (El-Serag and Davila, 2011). 
 
Study limitations 
There are certain limitations in systematic 
review studies, most notably in the absence of 
access to some of the information that at-
tempts were made to contact the authors of the 
study to resolve the problem, which in several 
cases did not receive an adequate response. 
One of the main limitation in our study was 
the failure to report sample size and the ina-
bility to calculate the confidence interval for 
survival, which did not allow the study to in-
clude the meta-analysis stage. Other limita-
tions included a survival report of less than 
one year (6 and 9 months), which, given the 
low level of these, had no significant effect on 
our results. Ultimately, due to the lack of stud-
ies reporting 10-year survival, the correct es-
timate of survival requires more robust stud-
ies. 
 
Recommendations for future research  
According to the results of this study, es-
timating the survival rate of LC requires more 
extensive studies at the level of other Asian 
countries, especially in the West and Central 
Asia, as most studies in this study were con-
ducted in South and Southeast of Asia, and es-
timates are somewhat incorrect. Another sug-
gestion could be a study of the survival of LC 
in patients who metastasized, which was not 
our study goal, and is an important issue in 
clinical decision-making and the continuation 
of treatment. 
 
CONCLUSION 
According to the results of our study, the 
LC survival rate in Asian countries is rela-
tively lower than in Europe and North Amer-
ica, which may be due to less access to diag-
nostic facilities and higher age at recognition 
of disease than to advanced countries. An-
other result of our study was the higher sur-
vival rate of LC in countries with very high 
HDI (such as South Korea and Japan), with 
similar survival rates within advanced coun-
tries such as Europe and North America. 
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